The Institute of Materia Medica Chinese Academy of Medical Sciences and the Peking Union Medical College have reported magnolol/honokiol nitrone derivatives acting as nitric oxide (NO) production inhibitors for the potential treatment of amyotrophic lateral sclerosis, traumatic brain injury, cerebral infarction, autoimmune disease, and respiratory tract and skin inflammation, among others.

Arvinas Operations Inc. has disclosed proteolysis targeting chimera (PROTACs) compounds comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety covalently linked to a B-cell lymphoma 6 protein (BCL-6)-targeting moiety through a linker with potential for use in the treatment of cancer.

Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has prepared and tested molecular glue degraders comprising E3 ubiquitin-protein ligases acting as proto-oncogene Vav (VAV1) degradation inducers reported to be useful for the treatment of inflammation and autoimmune diseases.

Simcere Zaiming Pharmaceutical Co. Ltd. has synthesized coumarin compounds targeting mitogen-activated protein kinase kinase reported to be useful for the treatment of cancer.

The Council of Scientific and Industrial Research has disclosed poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.

Scientists from Nanyang Biologics Pte. Ltd. and Nanyang Technological University have divulged molephantinin derivatives reported to be useful for the treatment of colorectal cancer.

Apex Biosciences Pte. Ltd. has identified phosphodiesterase (PDE) inhibitors reported to be useful for the treatment of arthritis, coronary artery diseases, idiopathic pulmonary fibrosis, inflammatory bowel disease, metabolic dysfunction-associated steatohepatitis, neurodegeneration, obstructive sleep apnea and cancer.

Abbisko Therapeutics Co. Ltd. has discovered GTPase KRAS mutant inhibitors intended for use in the treatment of cancer.

Ewha Womans University has identified new imidazopyridine or imidazopyrazine derivatives acting as Bruton tyrosine kinase (BTK) inhibitors potentially useful for the treatment of cancer and autoimmune disease.

Daiichi Sankyo Co. Ltd. has disclosed new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to a steroidogenic factor 1 (SF-1)-targeting moiety. They are reported to be potentially useful for the treatment of primary aldosteronism, Cushing syndrome and cancer.